[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surveillance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surveillance":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,78,110,135,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100629748","early-detection-of-metastatic-recurrence-among-patients-with-stage-ii-or-iii-triple-negative-breast-cancer-using-liquid-biopsy-and-imaging-100629748",false,"NCT07478705","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer (TNBC) Using Liquid Biopsy and Imaging: A Multi-Center Pilot Randomized Trial (EINSTEIN-TNBC)","EINSTEIN-TNBC","Inclusion Criteria:\n\n* Men or women aged 18 and over\n* Biopsy proven invasive triple negative breast cancer (defined here as estrogen receptor \\\u003C10%, progesterone receptor \\\u003C10%, human epidermal growth factor receptor 2 (HER2) negative status, with HER2 status being defined as per ASCO\u002FCAP guidelines)\n* T2-4\u002FN0 (\\>2 cm primary breast cancer as assessed clinically or on imaging in the absence of nodal involvement) OR T1c-4\u002FN1-3 disease (\\>10mm with fine needle aspirate or core biopsy confirming nodal involvement is required)\n* Residual disease (RCB 2 or 3) on surgical specimen after completion of neoadjuvant chemo(-immuno)therapy\n\nExclusion Criteria:\n\n* Inability to provide informed consent. Participants who require translators are allowed to enroll\n* Prior history of invasive breast cancer -Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the detection of BC recurrence on a liquid biopsy (patients with a history of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma-in-situ of cervix are permitted to participate)-\n* Pregnant patients are not permitted\n* Creatinine clearance \\\u003C45 mL\u002Fmin using the Cockcroft-Gault equation.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, often with poor outcomes. Currently, follow-up for TNBC consists of physical exams and annual breast imaging, with additional scans only if symptoms appear. This approach may delay the detection of the cancer coming back until the disease is advanced.\n\nA promising new technique is the detection of circulating tumor DNA (ctDNA)-in the blood. Studies suggest ctDNA may identify cancer recurrence months before it becomes visible on scans or causes symptoms. However, it is unknown whether detecting recurrence earlier can actually help patients live longer or feel better.\n\nThe EINSTEIN-TNBC trial is a study aiming to evaluate the feasibility of ctDNA-guided surveillance for patients with TNBC after surgery.\n\nThirty participants will be randomized to either:\n\nStandard of care (routine physical exams and annual breast imaging), or Active surveillance (standard of care plus ctDNA testing, with imaging investigations if ctDNA is detected).\n\nThis study will assess the feasibility of conducting a ctDNA-based monitoring trial in this patient population.\n\nIf feasible, EINSTEIN-TNBC will lay the foundation for a larger future clinical trial to determine whether earlier detection of metastatic TNBC can improve survival and quality of life.",[27,28,29,30],"Triple Negative Breast Cancer","Surveillance","Recurrence","ctDNA",[30,27,28,29],"NOT_YET_RECRUITING","2026-03-13",{"date":35,"type":36},"2026-03-17","ACTUAL",{"date":38,"type":21},"2026-05-01",{"date":40,"type":21},"2029-05-01",{"name":42,"class":43},"Sunnybrook Health Sciences Centre","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100602285","airway-complications-in-pediatric-patients-with-tracheostomies-to-what-extent-can-symptoms-identified-by-caregivers-or-pediatricians-serve-as-predictors-for-airway-complications-confirmed-through-surveillance-endoscopy-100602285","NCT07121517","\"Airway Complications in Pediatric Patients With Tracheostomies: To What Extent Can Symptoms Identified by Caregivers or Pediatricians Serve as Predictors for Airway Complications Confirmed Through Surveillance Endoscopy?\"","Inclusion Criteria:\n\nAll children, with tracheostomy, under the age of 18, undergoing scheduled surveillance airway endoscopy in anaesthesia as part of their regular follow-up at the Long term Intensive Care unit (LIVA) at Karolinska University Hospital are eligible for inclusion. Patients may be included several times during the study period.\n\nExclusion criteria:\n\nAll patients undergoing airway endoscopy that is not part of the surveillance airway endoscopy program will be excluded. Thus, emergency endoscopies are not included in this study.",{"count":51,"type":21},100,"2 Years","OBSERVATIONAL","Study Objective:\n\nThis observational study aims to prospectively investigate to what extent tracheostomy-related complications in children are asymptomatic or associated with symptoms when detected through surveillance airway endoscopy. We also aim at investigating how reliable caregiver reports and investigations by pediatriscians are in identifying symptoms associated with severe tracheostomy-related airway complications.\n\nStudy Population:\n\nThe study population comprises children under 18 years of age undergoing follow-up at the Long-Term Intensive Care Unit (LIVA) at Karolinska University Hospital in Stockholm, Sweden.\n\nResearch Questions:\n\n1. To what extent are tracheostomy-related complications in children asymptomatic when detected through surveillance airway endoscopy?\n2. How reliable are caregiver reports in identifying symptoms associated with tracheostomy-related airway complications?\n\nMethods:\n\nChildren scheduled for surveillance airway endoscopy are admitted to LIVA. Upon admission, the caregiver is asked to complete a short questionnaire regarding symptoms that may indicate a tracheostomy-related complication.\n\nAfter the questionnaire has been completed, the child will be examined by the responsible paediatrician, with the aim of identifying any signs or symptoms that could indicate an airway complication. The examination includes physical examination and medical history conducted according to a predefined protocol.\n\nThe airway endoscopy is performed by an ENT surgeon who has not examined the patient beforehand and is not informed of the caregiver's responses nor the result of the examination by the pediatrician. However, there is no strict protocol in place to blind the surgeon to any visibly apparent symptoms or to information that may be spontaneously reported by the caregiver or paediatrician.",[28,56,57,58,59,60],"Endoscopy","Tracheostomy Complication","Tracheostomy Complications","Tracheostomy","Children in the Pediatric Intensive Care Unit or General Pediatric Care Unit Requiring a Central Venous Catheter",[62,63,64,65,66],"surveillance","endoscopy","pediatric","intensive care unit","tracheostomy complication","RECRUITING","2026-02-12",{"date":70,"type":36},"2026-02-17",{"date":72,"type":36},"2025-09-01",{"date":74,"type":21},"2027-08-31",{"name":76,"class":43},"Karolinska Institutet",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":77},"100619489","clinical-aspects-management-and-surveillance-of-febrile-illnesses-in-drc-100619489","NCT07345286","Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC","Aspects Cliniques, Prise en Charge et Surveillance Des Maladies fébriles en RDC","FI-CARE","Inclusion Criteria:\n\n* Ongoing fever objectified at presentation, or documented at home or other health center within 24 hours prior to presentation, defined as: axillary or tympanic temperature \\> 37.5°C, or oral or rectal temperature \\> 38°C.\n* Opportunity for contact between patient (or designated relative) and study team on days 7, 14 and 21.\n* Informed consent to participate signed by the patient (adult) or a legally acceptable representative (child or patients whose condition does not allow them to sign informed consent), with the assent of children aged 12 and over, wherever possible.\n\nExclusion Criteria:\n\n* Child less than two months old.\n* Hospitalization of \\> 48h in the last 14 days.",true,"2 Months",{"count":89,"type":21},500,"The epidemiology and outcome of febrile illnesses in the Democratic Republic of Congo (DRC) is poorly documented. The FIKI² study, a prospective observational study of community-acquired febrile illnesses coordinated by ITM and INRB and conducted at 2 clinical sites from 2021 to 2023, has deepened the knowledge of clinical presentation, etiology, outcome and profile of inflammatory\u002Finfectious biomarkers (white blood cells and C-reactive protein, or CRP).\n\nThe management of febrile illnesses remains fraught with clinical challenges. Overuse of antibiotics in primary care remains a reality in the field, and has been observed in several studies, including FIKI². A number of initiatives are underway to address this problem, such as the use of biomarkers, the development of treatment guidelines and electronic decision support systems. The FIKI² study highlighted the potential role of CRP in rationalizing antibiotic use. In parallel, the 'AWARE antibiotic book' was published at the end of 2022 by the WHO, providing recommendations on the choice (or otherwise) of antibiotic therapy for over 30 common clinical infections, in both primary care and hospital settings.\n\nBased on the results of the FIKI² study, the main aim of the FI-CARE study is to investigate the impact of these new tools (CRP biomarker, AWARE antibiotic book, and electronic decision support systems) on first-line antibiotic use. Secondly, the study will consolidate previous results from FIKI² sites in terms of monitoring the etiologies of community-acquired febrile illnesses (particularly arboviruses); and reinforce this monitoring at new sites (depending on opportunities). This complementary study will also pursue FIKI²'s strategic objectives of strengthening clinical research capacity and consolidating biobanks in the DRC.\n\nFI-CARE is a prospective, observational, multicenter cohort study of adults and children presenting to the emergency department or outpatient clinic with community-acquired febrile illness. A laboratory component with sample storage in a biobank is added in a modular fashion according to laboratory and research capacities, epidemiological interest and available funds.",[92,93,28],"Febrile Illness Acute","Biomarkers",[95,96,97,62,98,99,100],"febrile illness","CRP","biomarkers","clinical characteristics","Subsaharan Africa","malaria","2026-01-09",{"date":103,"type":36},"2026-01-15",{"date":105,"type":36},"2025-01-20",{"date":107,"type":21},"2027-01-01",{"name":109,"class":43},"Institute of Tropical Medicine, Belgium",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100519159","effect-of-the-automatic-surveillance-system-on-surveillance-rate-of-patients-with-gastric-premalignant-lesions-100519159","NCT06039917","Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions","Inclusion Criteria:\n\n* Male or female aged 18 years or older who undergo upper endoscopy.\n\nExclusion Criteria:\n\n* 1)No contact information or invalid contact information.\n* 2\\) The surveillance interval cannot be determined according to the surveillance guidelines, including no upper gastrointestinal pathology, therapeutic endoscopy or with history of previous gastrectomy, esophagectomy, or ESD, no dysplasia degrees, no biopsy sites, non-epithelial lesions, duodenal lesions, ulcer and so on.\n* 3\\) Needless for surveillance or others.\n* 4\\) High-grade intraepithelial neoplasia or cancer of the esophagus or stomach.\n* 5\\) Low-grade intraepithelial neoplasia of the esophagus and Barrett's esophagus.\n* 6\\) High-risk diseases or other special conditions for which the patient is deemed unsuitable for clinical trials by the investigator.",{"count":117,"type":21},1460,[24],"In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of patients with gastric premalignant lesions. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups will be compared.",[121,28],"Artificial Intelligence",[123,124],"surveillance rate","automatic surveillance","2024-11-01",{"date":127,"type":36},"2024-11-04",{"date":129,"type":36},"2023-09-10",{"date":131,"type":21},"2029-12-31",{"name":133,"class":43},"Renmin Hospital of Wuhan University",4,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":77},"100508011","effect-of-the-automatic-surveillance-system-on-surveillance-rate-of-colorectal-postpolypectomy-patients-100508011","NCT05894850","Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients","Inclusion Criteria:\n\n* Male or female aged 18 years or older who undergo colonoscopy.\n\nExclusion Criteria:\n\n* 1)No pathological result.\n* 2\\) No or invalid contact information.\n* 3\\) The surveillance interval cannot be determined according to the surveillance guidelines, including poor bowel preparation, colorectal cancer or suspicious malignance, surgery or colorectal ESD history, those who fail to complete colonoscopy due to unbearable, pathological indications of not polyps, hamartoma or lymphoma polyps, history of ulcerative colitis, and so on.\n* 4\\) Has participated in other clinical trials, signed the informed consent form and is in the surveillance period of other clinical trials.\n* 5\\) Have drug or alcohol abuse or psychological disorder in the past five years.\n* 6）Pregnancy.\n* 7）Not suitable for recruitment after investigator evaluation because of other high-risk conditions.",{"count":142,"type":21},1644,[24],"In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system reminding though telephone and message, group B with intelligent surveillance system reminding though message, group C with manual reminder, and group D with natural state. The surveillance among the four groups were compared.",[121,28],[123,124],"2023-06-07",{"date":149,"type":36},"2023-06-08",{"date":151,"type":21},"2023-06-01",{"date":131,"type":21},{"name":133,"class":43},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":172,"locationsCount":173},"100497021","evaluating-the-effect-of-the-automatic-surveillance-system-on-surveillance-rate-of-colorectal-postpolypectomy-patients-100497021","NCT05751824","Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients","Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients: A Prospective, Multicenter Study",{"count":161,"type":21},867,[24],"In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups were compared.",[121,28],[123,124],"2023-03-07",{"date":168,"type":36},"2023-03-09",{"date":170,"type":21},"2023-02-26",{"date":131,"type":21},{"name":133,"class":43},2]